CCHR Welcomes State Actions that Ban or Restrict Behavioral Restraint Use
The mental health watchdog, CCHR, supports states taking action to prohibit or restrict lethal physical or chemical restraint use in police and psychiatric settings in…
The mental health watchdog, CCHR, supports states taking action to prohibit or restrict lethal physical or chemical restraint use in police and psychiatric settings in…
Rev. Shaw from the group’s Racism Task Force also cautions African Americans against offers to treat racial trauma with psychedelics, citing history of racist psychiatric…
CCHR increases its monitoring of FDA approval of nasal spray antidepressant and mental health apps that could increase psychotropic drug use, leading to increased suicide….
Low doses of psychedelic drugs, including lysergic acid diethylamide (LSD), ketamine, and psilocybin, may reduce clinical symptoms in patients with depression, anxiety, obsession-compulsive disorders (OCDs), and chronic pain, without inducing depersonalization or hallucinations, according to a new Perspectives article published online August 18 in Nature Reviews Neuroscience.